BRIEF-GSK announces positive final stage results for two-drug HIV treatment
Feb 14 GlaxoSmithKline Plc :
* VIIV phase III results dolutegravir & rilpivirine
* Announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment
* In sword studies, two-drug regimen showed comparable efficacy to three- or four-drug regimens in virologically suppressed patients
* Headline results were announced in December 2016
* Use of dolutegravir and rilpivirine as a two-drug regimen for hiv-1 maintenance therapy is investigational and not approved anywhere in world Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)